Novartis’ Cancer Drug (Gleevec) vs. the Supreme Court of India: a Classic Catch-22?

Indian Supreme Court

The ruling the other day by the Indian Supreme Court to deny Swiss global pharmaceutical company Novartis AG’s patent appeal for its cancer drug Gleevec (Imatinib) has been called landmark for many reasons. In fact, there have been dozens, if not hundreds of articles in newspapers, journals, blogs and much coverage in all media. Here are but a few examples that are not intended by any means to be exhaustive but merely illustrative of the …

     

Sometimes Big GAMBLES Really Pay Off…

gamble-throwing-dice

Twice in my career I have taken what I considered to be a big gamble. One where I didn’t really know what was going to happen to me down the path, but where I was willing to take a big risk. The first of these was in 1981, when fresh out of a post-doctoral fellowship at the University of Calgary Medical School I decided to turn down a faculty position at the University of British …

     

It’s Time to Dust Off the Cobwebs…

cobweb

This is not the kind of blog post I normally write, but for those of you who have been following this blog (assuming there are any of you left!) you will see that I have written very little (i.e. nothing) for many months now. For those who have been kind enough to inquire about my health and well-being, I thank you very much but I can assure you that I am very well indeed. I …